Sanofi will receive up to $ 9.5 billion biopharma group biofarma group

By Dominique Patton and Geert de CLCQ

Paris (Reuters) -France’s Sanofi, According to LSEG, the Blueprint Medicinal Corporation in the United States has reached $ 9.5 billion to increase its position in unique immunological diseases.

Blueprint is a specialist in treatment for a unique blood disorder systematic mastocytosis.

Two companies said Sanofi will first pay $ 129.00 per cash or $ 9.1 billion in Monday. Blueprint shares dropped from 27% to $ 128.74 with premarket trade. Sanofi Stock has decreased by about 1%.

Sanofi has increased research and development costs in recent years, so that the company’s long-term profit margin and other conditions can increase the success of the blockbuster medicine for the long-term profit margin.

However, a series of consistent drugs last week has generally gave an unsuccessful result for patients with “smoking” pulmonary “.

The purchase of Blueprint “makes a strategic step in our rare and immunological portfolio. This increases our pipeline and accelerates our region to become a leading immunology company,” Sanofi CEO Paul Hudson said.

NORRE immunological diseases, known as a rare immunological disease medicine, ayrical immunological disease medicine Ayvakit, Ayvakit, US and EU, will add drugs to drugs.

Ayvakit, advanced and sensitive systematic mastocytosis, the body’s abnormal mast cells – a type of white blood cell is the only approved drug for a rare blood disorder. Triggers a continuous allergic response.

The Acquisition Would Also Bring Elenestinib, A Next-Generation Medicine For Systemic Mastocytosis, as Well as Blu-808, A Highly Selective and Potent Oral Wild-Type KIT Inhibitor Type Has The Potential To Treat A Broad Range of Diseases in Immunology.

The deal is “Strategic and Finance Meaning,” Morgan’s analysts said that Blueprint said that Ayvakit’s Ayvakit expects to increase about $ 2 billion by the financial year of the 2030.

“We see the operation as a suitability in a sensitive assessment that investors must see in vain positive over time,” he said.

It is the latest in a number of deals by Sanofi. Last month, this announced a $ 470 million countdown, and in January 2024, US Biotech firms a $ 2.2 billion contract for inhibition.

Hudson said the deal was completed by Sanofi’s final purchase of other early staged medicines and has kept a large capacity for more growing deals.